ArticleVaccine2020
Durability of humoral immune responses to rubella following MMR vaccination.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Completeness of MMR Vaccination and Durability of Vaccine-Induced Antibody Responses in Children with Inflammatory Bowel Disease.Biomedicines · 2026Article
- Duration of vaccine-induced immunity following MMR2 vaccination in a measles and rubella-eliminated country.International journal of epidemiology · 2026Article
- Factors influencing post-vaccination antibody levels to measles and rubella in children with inflammatory bowel disease.Immunologic research · 2026Observational
- Loss of measles, mumps, and rubella immunity in pediatric cancer survivors following chemotherapy.BMC research notes · 2025Article
- Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose.Viruses · 2025Article
- Long-term trends in rubella incidence across various regions and age groups in China, 2004-2021.Frontiers in public health · 2025Article
- Rubella epidemiology in Lesotho after vaccine introduction: a five-year review, 2018-2022.BMC public health · 2024Article
- Long-term Neutralizing Antibody Levels Against Measles and Rubella Viruses Among Adults With 3 Doses of Measles-Mumps-Rubella Vaccine.Open forum infectious diseases · 2024Article
- The frequency of IgG anti-varicella and anti-rubella antibodies in female students of Shiraz University of Medical Sciences, Iran.Le infezioni in medicina · 2023Article
- Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents.Clinical immunology (Orlando, Fla.) · 2022Article
- Sex-specific effects of aging on humoral immune responses to repeated influenza vaccination in older adults.NPJ vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundWhile administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults.
methodsIn this longitudinal study, we sought to assess the durability of rubella virus (RV)-specific humoral immunity in a healthy population (n = 98) of adolescents and young adults at two timepoints: ~7 and ~17 years after two doses of MMR-II® vaccination. Levels of circulating antibodies specific to RV were measured by ELISA and an immune-colorimetric neutralization assay. RV-specific memory B cell responses were also measured by ELISpot.
resultsRubella-specific IgG antibody titers, neutralizing antibody titers, and memory B cell responses declined with increasing time since vaccination; however, these decreases were relatively moderate. Memory B cell responses exhibited a greater decline in men compared to women.
conclusionsCollectively, rubella-specific humoral immunity declines following vaccination, although subjects' antibody titers remain well above the currently recognized threshold for protective immunity. Clinical correlates of protection based on neutralizing antibody titer and memory B cell ELISpot response should be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.